Verena Pfister

Verena Pfister

Auto-generated profile, based on publicly available information

Verena Pfister

Universidade Federal de Sao Paulo, Sao Paulo, Brazil

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 May 2022 in eJHaem
Verified
Journal Article
Open access
VPVerena Pfister
Verena Pfister
FMFernanda de Morais Marques
Fernanda de Morais Marques
FPFlavia Parra
Flavia Parra
MYMihoko Yamamoto
Mihoko Yamamoto
MGMatheus Vescovi Gonçalves
Matheus Vescovi Gonçalves
CACelso Arrais‐Rodrigues
Celso Arrais‐Rodrigues
Chronic lymphocytic leukaemia (CLL) has a highly variable clinical course. In addition to biological factors, socioeconomic factors and health system characteristics may influence CLL outcome. Data from the Brazilian Registry of CLL were analyzed to compare clinical and treatment‐related characteristics in patients with CLL, from public or private institutions. A total of 3326 patients from 43 centres met the eligibility criteria, of whom 81% were followed up at public hospitals and 19% at private hospitals. The majority were male (57%), with a median age of 65 years. Comparing public and private hospitals, patients in public hospitals were older, had more advanced disease at diagnosis, and more frequently had elevated creatinine levels. All investigated prognostic markers were evaluated more often in private hospitals. First‐line treatment was predominantly based on chlorambucil in 41% of the cases and fludarabine in 38%. Anti‐CD20 monoclonal antibody was used in only 36% of cases. In public hospitals, significantly fewer patients received fludarabine‐based regimens and anti‐CD20 monoclonal antibodies. Patients from public hospitals had significantly worse overall survival (71% vs. 90% for private hospitals, p < 0.0001) and treatment‐free survival (32% vs. 40%, for private hospitals, p < 0.0001) at seven years. Our data indicate striking differences between patients followed in public and private hospitals in Brazil. A worse clinical condition and lack of accessibility to basic laboratory tests and adequate therapies may explain the worse outcomes of patients treated in public institutions.

16 January 2026 in Blood Advances
Verified
Journal Article
Open access
TCThomas Chatzikonstantinou
Thomas Chatzikonstantinou
MMMariia Mikhaleva
Mariia Mikhaleva
CBChristian Brieghel
Christian Brieghel
CPChristina Papangelou
Christina Papangelou
EMEva Minga
Eva Minga
MKMaya Koren-Michowitz
Maya Koren-Michowitz
Central nervous system involvement (CNSi) of chronic lymphocytic leukemia (CLL) is a rare condition with no consensus on diagnostic criteria and limited evidence for management and outcome. Here, we report an international, multicenter, retrospective study conducted by the European Research Initiative on CLL. The study defined CNSi of CLL by the following: (1) detection of CLL cells in the cerebrospinal fluid or confirmation of CLL infiltration of the CNS based on a tissue biopsy, (2) clinical or radiographic evidence of neurologic disease, and (3) the absence of other explanations for the neurologic findings. A total of 48 patients from 26 centers in 15 countries met all 3 diagnostic criteria of CLL-CNSi. Median age at diagnosis of CNSi was 64 years. Most patients were males (73%), had Binet stage A at CLL diagnosis (61%), and had untreated CLL at the time of CNSi (63%). Motor impairment was the most common symptom (38%) followed by visual impairment (32%). Of 47 patients who received treatment for CNSi, half (51%) received targeted agents, most often a Bruton tyrosine kinase inhibitor (BTKi), and 34% received chemoimmunotherapy. Initial treatment was highly effective, leading to a reduction (83%) or complete resolution (71%) of neurologic symptoms and imaging findings in most patients. The estimated 5-year overall survival (OS) from the CNSi diagnosis was 77.1%. The 5-year time to next treatment or death was 94% for patients treated with BTKi compared with 64% for those treated with CIT. Treatment-sensitive disease, represented by attainment of CNS complete response after initial therapy, was associated with longer OS.

18 July 2025 in Blood Global Hematology
Verified
Journal Article
Open access
VPVerena Pfister
Verena Pfister
FMFernanda de Morais Marques
Fernanda de Morais Marques
TSTalita Silveira
Talita Silveira
JFJayr Schmidt Filho
Jayr Schmidt Filho
VMVinicius Campos de Molla
Vinicius Campos de Molla
CACelso Arrais-Rodrigues
Celso Arrais-Rodrigues